Carbocisteine should be initiated by secondary care respiratory physicians for chronic cough productive of sputum as outlined in
|
NICE guidance. Therapy should only be continued if there is symptomatic improvement e.g. reduction in frequency of cough and
|
sputum production.
|
| |
| capsules 375mg |
| sachets -750mg/10ml sugar-free oral solution in sachet |
| (2nd line choice for adults with COPD and swallowing difficulties) |
| RED Oral Solution 250mg/5ml (paediatric use only) |
RED Dornase alfa nebuliser solution 1mg/ml*
|
RED Mannitol, dry powder inhalation 40mg capsules
|
| |
* Dornase alfa is RED Traffic Light where prescribing has been initiated on or after 1st April 2013.
|
Where prescribing was initiated prior to April 1st 2013 the traffic light status may remain amber until repatriation of patients has
|
been agreed by NHS England, local commissioners and providers.
|
| |
Hypertonic sodium chloride
|
Inhaled hypertonic saline is a widely-used and well-accepted therapy for increasing the mucilliary clearance in the lower airways in
|
patients with cystic fibrosis. Patients especially benefit from sputum expectoration due to osmotic effects of hypertonic saline.
|
Different doses and concentrations are used in common therapy. The DTC has supported the use of this product .The efficacy and
|
tolerability of hypertonic saline has been demonstrated in several clinical trials.
|
| |
| AMBER Mucoclear® (Sodium chloride 3% solution for inhalation) [PRESCRIBE BY BRAND] |
AMBER Resp-Ease® (Sodium chloride 7% solution for inhalation) [PRESCRIBE BY BRAND]
|
RED All other unlicensed products and strengths
|
| |
| Mucolytic [Palliative Care, Tracheostomy] |
| Breathlessness - See page 8 & 19 Consensus Approach to Managing Palliative Care Symptoms Clinical Practice Summary |
| Tracheostomy use. |
| GREEN Sodium Chloride 0.9% for nebulisation [Respi-Clear® 20 x 2.5ml, Salineb® 20 x 2.ml] |
| PRESCRIBE BY BRAND |
back to main page
|
| |
All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
|
public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service
|
| Email: info.elmmb@nhs.net |
|
| Copyright© 2019 East Lancashire Medicines Management Board. |
| All rights reserved. Disclaimer/Terms and conditions |
